|Videos|August 9, 2016

Strategies to Prevent Infection Transmission in Outpatient Settings

Matt Linam, MD, MS, medical director of Infection Prevention at Arkansas Children’s Hospital, discusses strategies to prevent infection transmission in outpatient settings.

Matt Linam, MD, MS, medical director of Infection Prevention at Arkansas Children’s Hospital, discusses strategies to prevent infection transmission in outpatient settings.

Interview Transcript (slightly modified for readability).

“Things like hand hygiene and making sure that you’re not ill as well as some other strategies can be applied in the outpatient setting. Again, doing hand hygiene frequently is a really important way to keep yourself from potentially contaminating your hands and then inoculating yourself.

Performing good cough etiquette, making sure that you’re covering your cough [by] coughing into your elbow instead of your hands, is a good way to protect those around you, whether you’re in an office setting, school or daycare.

It’s hard for us to miss work or school and not send our kids to daycare if they’re sick, but it really is important because when someone goes to school or daycare and they’ve got some sort of contagious illness, that just furthers the spread to the children around them.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.